Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helen Katrina Tayton-Martin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Beta
- 0.27
- Country
- DK
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -8.94
Financials
Revenue
$0.00-100.0%Net Income
$-3.72MEBITDA
$-3.84MFree Cash Flow
$0.00EPS (diluted)
$-9.00Shares Outstanding (diluted)
417.0K-13.1%Operating Expenses
$3.84MCash & Debt
$14.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.53M | $-7.71M | $-1.21 |
| 2024 | $3.34M | $-10.57M | $-9.80 |
| 2023 | $73.0K | $-22.13M | $-32.40 |
| 2022 | $0.00 | $-23.17M | $-39.20 |
| 2021 | $0.00 | $-24.53M | $-50.40 |
| 2020 | $0.00 | $-15.02M | $-37.00 |
| 2019 | $0.00 | $-11.19M | $-27.60 |
| 2018 | $0.00 | $-5.54M | $-11.52 |
Valuation
EVAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·22d ago·Positive
…ein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026 COPENHAGEN, Denmark, September 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI- Immunology™ platform, has begun the application of the platform in autoimmune diseases thereby expanding the company's therapeutic focus and achieving another company milestone for 2026.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Evaxion announces business update and second quarter 2026 financial results COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026 COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM.
View source ↗
Earnings
Thu, Nov 19(in 6 weeks)
Consensus estimate $-0.01 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.01 vs $-0.01beat
- Tue, May 26$-0.01 vs $-0.01beat
- Thu, Mar 5$-0.02 vs $-0.24beat
- Thu, Oct 30$0.01 vs $-0.01beat
- Thu, Aug 14$-0.76 vs $-0.50miss
- Tue, May 27$-0.29 vs $-0.65beat
Estimates and results for EVAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EVAX officers and directors.
No open-market trades in the recent filings. All 80 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EVAX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.